MedPath

New data from TAR-200 Phase 2b SunRISe-1 study show 84 - GlobeNewswire

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9.2 months, highlighting its potential as a bladder-sparing treatment alternative to radical cystectomy.

Related Clinical Trials

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Reference News

globenewswire.com
New data from TAR-200 Phase 2b SunRISe-1 study show 84 - GlobeNewswire

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9.2 months, highlighting its potential as a bladder-sparing treatment alternative to radical cystectomy.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy